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1. Introduction 
Hepatocellular carcinoma (HCC) is the most 
common form of primary liver cancer and the 
second leading cause of cancer-related deaths 
worldwide [1]. WHO estimates that in 2030 over 
1 million people will die from liver cancer [2]. 
Due to its high prevalence, HCC has become a 
global economic burden on society. Risk factors 
for HCC include Hepatitis B or C infection, 
excessive alcohol intake and non-alcoholic fatty 
liver disease [2]. In 80%-90% of patients, HCC 
develops from cirrhosis, a chronic liver condition 
that also affects the hepatic architecture [1]. In 
patients unfit for tumor resection, HCC can be 
treated by transarterial chemoembolization 
(TACE) or radioembolization (TARE). During 
these procedures, embolic microparticles are 
injected in a branch of the proper hepatic artery 
(PHA), which either emit a high-intensity beta-
radiation (TARE) or carry chemotherapeutic 
agents (TACE) to permanently damage the 
tumor tissue [3]. The goal is to direct particles 
towards the tumor, increasing the efficiency of 
the therapy and limiting the offsite toxicity 
delivered to healthy tissue. Due to the 
complexity and tortuosity of the arterial network, 
it is often challenging to navigate catheters 
towards the tumor tissue. Therefore, easily 
accessible upstream injection locations need to 
be identified without compromising the target-
specificity of the procedure. The goal of this 
research is to investigate the impact of tumor 
burden (i.e. tumor size, location) on the particle 
distribution in a patient-specific cirrhotic liver 
and to assess the possibility of targeting solid 
tumor(s) by injection from specific upstream 
injection locations.  
 
2. Methods   
 
The dataset of a patient-specific cirrhotic liver 
was obtained by combining vascular corrosion 
casting and micro-CT imaging [4]. The hepatic 
arterial network was segmented based on the 
contrast difference between parenchyma, 
arteries and veins using Mimics software 
(Materialise, Leuven, Belgium). A 3D 
reconstruction of the arterial network was made 
(see Figure 1). Arteries were truncated at the 4th 
or 5th generation to reduce computational 
complexity. A volume mesh containing 9∙106 
tetrahedral elements was created in ICEM CFD 
(Ansys Inc., Canonsburg, USA.)  
 
The blood flow (continuous phase) and the 
particle mass transport (discrete phase) were 
simulated using Fluent (Ansys Inc., 
Canonsburg, USA). Six cancer cases were 
defined: a small (135 ml), moderate (565 ml) or 
large tumor (1130 ml) confined to either the left 
(Case 1-3) or the right lobe (Case 4-6) of the 
liver. Inlet and outlet boundary conditions were 
set according to the methodology described by 
Aramburu et al. [5]. Aramburu’s perfusion model 
considers that the arterial perfusion of tumor 
tissue is at least four times larger than the 
perfusion of healthy tissue, which significantly 
increases arterial flow in the branches perfusing 
the tumor tissue (i.e. higher outflow fraction).  At 
the inlet, a steady blood flow was imposed, 
depending on the tumor burden. Since tumors 
derive their blood supply mainly from the 
hepatic artery, higher tumor burden is 
associated with an increase in hepatic artery 
blood flow [5]. For a small tumor (Case 1 and 4), 
a blood inflow of 306 ml/min was set; for a 
moderate tumor (Case 2 and 5), 484 ml/min, 
and for a large tumor (Case 3 and 6), 718.5 
ml/min. At the 21 outlets, a fractional outflow 
distribution was imposed.   
 
For post-processing, Particle Release Maps 
(PRMs) were calculated by projecting particle 
destination (i.e. through which outlets of the 
computational domain the particles exit) on the 
injection plane. As visible in Figure 1, the color-
coded PRMs show in which sections of the 
injection plane particles should be injected to 
target certain specific outlets of the 
computational domain.  
 
3. Results and Discussion  
 
In Figure 2, the PRMs for each of the six cancer 
scenarios are given (top row: tumor(s) confined 
to left lobe, bottom row: tumor(s) confined to  
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Figure 1: PRMs are color-coded projections of 
particle fate on the injection plane (0: no exit, 
1-21: outlet through which the particles exit).  
right lobe, left to right: increasing cancer 
burden). The PRMs for Case 1-3 (top row, 
Figure 2) clearly show that, as cancer burden in 
the left lobe increases, more particles flow to the 
left lobe (i.e. outlets 17-21). This effect is also 
evident in Table 1: particle fraction for the left 
lobe (LL) increases for increasing tumor burden, 
while the particle fraction for the right lobe  (RL) 
decreases significantly (Case 1-3). The PRMs 
for Cases 4-6 (bottom row, Figure 2) also show 
that more particles will flow towards the right 
lobe (i.e. outlets 1-16) for higher tumor burden 
in the right lobe, but this effect is much less 
outspoken than in the left lobe cases. This is 
also visible in Table 1. The fraction of particles 
exiting the right lobe increases only 6.5% from 
low to high right tumor burden (RL, Cases 4-6), 
while the left lobe fraction increases almost 27% 
from low to high left tumor burden (LL, Cases 1-
3).  
 
Figure 2: PRMs for the 6 cancer cases. 
The results show that by carefully controlling the 
radial in-plane location of the catheter tip 
particles may be steered towards specific exit 
branches. Based on the patient-specific data 
above, targeting downstream solid tumor(s) 
may become easier as cancer burden and 
arterial flow to the tumor(s) increase. However, 
these results are highly patient-specific and 
cannot yet be generalized for other cases.  
 
 
Table 1: Particle distribution fractions in left 
lobe (LL) and right lobe (RL) for the 6 cases. 
There was also significant particle deposition 
(PD) in the domain (i.e. particles which didn’t 
exit through any outlet). 
4. Conclusions  
 
This work represents the first step in modelling 
locoregional drug delivery in the liver with the 
overall aim of identifying easily accessible 
injection locations where particles can be 
steered towards tumor tissue by careful control 
of radial catheter tip location.  PRMs are helpful 
tools in identifying the regions of the injection 
plane where particle release leads to particle 
deposition in the tumor tissue. Future work will 
focus on including transient simulations and in 
vivo validation of the models.  
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 Case 1 Case 2 Case 3 
LL (%) 29.96 49.95 56.57 
RL (%) 58.49 35.86 24.83 
PD (%) 11.55 14.20 18.60 
 Case 4 Case 5 Case 6 
LL (%) 13.99 9.56 7.60 
RL (%) 74.71 80.71 81.20 
PD (%) 11.30 9.73 11.20 
